Collecting Duct (Bellini Duct) Renal Cell Carcinoma: A Nationwide Survey in Japan

Tokuda, Noriaki; Naito, Seiji; Matsuzaki, Osamu; Nagashima, Yoji; Ozono, Seiichiro; Igarashi, Tatsuo

doi:10.1016/s0022-5347(06)00502-7

Cited by 158 publications

(155 citation statements)

References 8 publications

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…The largest case series to consider outcome to date was reported from Japan and consisted of 81 patients. 21 Regional lymph node metastases were present in 44% of the patients in this series at diagnosis, whereas 32% had distant metastases. The 1-, 3-and 10-year disease-specific survivals in this series were 69, 45 and 14%, respectively.…”

Section: Collecting-duct Carcinomamentioning

confidence: 64%

Uncommon and recently described renal carcinomas

2009

View full text Add to dashboard Cite

Major consensus conferences held over a decade ago laid the foundations for the current (2004) WHO classification of renal carcinoma. Clear cell, papillary and chromophobe carcinomas account for 85-90% carcinomas seen in routine practice. The remaining 10-15% of carcinomas consist of rare sporadic and hereditary tumors, some of which had been long recognized, but many of which only emerged as distinct entities in the decade leading up to the WHO publication. Collecting-duct carcinoma is a rare, often lethal form of carcinoma. Medullary carcinoma associated with sickle cell trait, has emerged as a distinctive tumor showing some overlapping features with upper tract urothelial carcinoma. Mucinous tubular and spindle-cell carcinoma and tubulocystic carcinoma were earlier considered as patterns of low-grade collecting-duct carcinoma, but are now recognized as separate tumor entities. Carcinomas associated with somatic translocations of TFE3 and TFEB comprise a significant proportion of pediatric renal carcinomas. Oncocytoid renal carcinomas in neuroblastoma survivors was recognized as a unique tumor category in the WHO classification. Renal carcinoma associated with end-stage renal disease is now recognized as having distinct morphological patterns and behavior. In addition there is a group of rare recently described carcinomas, including clear cell papillary carcinoma, oncocytic papillary renal cell carcinoma, follicular renal carcinoma and leiomyomatous renal cell carcinoma. It behooves the surgical pathologist to not only be capable of diagnosing the common forms of renal cancer, but also to be aware of the rare types of renal carcinoma, many of which have emerged in recent years.

show abstract

Section: Collecting-duct Carcinomamentioning

confidence: 64%

Uncommon and recently described renal carcinomas

2009

View full text Add to dashboard Cite

show abstract

“…Recently published series [1][2][3] and conventional secondary sources 9 do not provide direction on the appropriate management of cdc. It is for that purpose that we report the results of a systematic review addressing the management of cdc.…”

Section: Discussionmentioning

confidence: 99%

“…Additionally, those series indicated that more than two thirds of patients with cdc exhibit locoregional or systemic symptoms on presentation. The most common metastatic sites included regional lymph nodes, lung, bone, and liver 3 .…”

Section: Introductionmentioning

confidence: 99%

Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster Experience

et al. 2013

View full text Add to dashboard Cite

Introduction: Collecting duct carcinoma (CDC) is a rare, aggressive form of renal carcinoma that presents at an advanced stage and has a poor prognosis. Little is known concerning the optimal management of CDC. We present the results of a systematic review addressing the management of CDC and the McMaster University CDC series. Methods: The MEDLINE, Cochrane Library, and EMBASE databases and conference proceedings were searched to identify studies relating to the management of CDC. Included studies reported on a minimum of 10 subjects receiving a single intervention. Series in which an evaluation of therapeutic effectiveness was not possible were excluded. The McMaster University (Hamilton, Ontario) series of 6 cases of CDC were retrospectively reviewed. Results: We identified 3 studies relevant to the management of CDC that included a total of 72 patients. A gemcitabine–cisplatin or –carboplatin regimen resulted in a 26% objective response rate in 23 patients with metastatic CDC. Two additional studies indicated that 49 patients treated with immunotherapy achieved no response. In the McMaster series, cytoreductive nephrectomy was performed in 4 of 6 patients. In 2 patients, MVAC therapy (methotrexate–vinblastine–doxorubicin–cisplatin) achieved no response. No significant therapeutic complications occurred, but survival was poor (median: 11 months; range: 10–33 months). Conclusions: Our review and clinical experience suggest that the current standard of care for metastatic CDC is a gemcitabine–cisplatin regimen.

show abstract

“…The chances of surviving a renal cell cancer without surgery are small [5]. Many cases of RCC have been successfully treated by surgical resection at the early stages of the disease; this has been facilitated by advances in radiologic imaging [78]. Patients that are not surgical candidates may be subjected to ablation therapy [5].…”

Section: Treatmentmentioning

confidence: 99%

“…Notwithstanding significant advances in RCC-therapeutics in the past decade, no standard treatment has been identified for advanced chromophobe RCC [6]. An effective therapy has also not been established for human Collecting Duct Carcinoma CDC [65], which is known to have an unfavorable prognosis due to high frequency of postoperative recurrences and distant metastases [78]. Multimodal therapy including surgery should be considered for patients with metastatic RCC [79].…”

Section: Treatmentmentioning

confidence: 99%

Renal Cell Carcinoma in Humans and Animals: A Brief Literature Review

Woldemeskel¹

2013

J Clin Exp Pathol

View full text Add to dashboard Cite

Renal Cell Carcinoma (RCC) is the most common primary renal neoplasm in humans and domestic animals such as dogs, cats and horses. Various subtypes are recognized in both humans and animals. Advances in biomedical sciences have developed hitherto unprecedented extraordinary cancer therapeutic options varying from sophisticated surgery to immunotherapy and gene therapy. Treatment regimens employed, response to treatments and prognosis vary based on the subtypes of RCC, degree of malignancy, metastasis and stage of the neoplasm. Surgery is the main treatment for most RCCs. Drug resistance has long been a challenge in cancer treatment. New insights in cancer treatment such as molecular targeted therapy including nano-medicine against chemo-resistance are among the contemporary developments targeting cancers. This mini review highlights on the occurrence and significance of RCC in humans and animals, briefly summarizes the various subtypes reported and the treatment regimens executed.

show abstract

Collecting Duct (Bellini Duct) Renal Cell Carcinoma: A Nationwide Survey in Japan

Abstract: We report what is to our knowledge the largest known series of collecting duct carcinoma. Since advanced or recurrent collecting duct carcinoma is resistant to standard treatment modalities, new treatment strategies are needed for advanced collecting duct carcinoma.

Cited by 158 publications

References 8 publications

Uncommon and recently described renal carcinomas

Uncommon and recently described renal carcinomas

Management of Renal Collecting Duct Carcinoma: A Systematic Review and the McMaster Experience

Renal Cell Carcinoma in Humans and Animals: A Brief Literature Review

Contact Info

Product

Resources

About